Company Overview of ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
3611 Valley Centre Drive
San Diego, CA 92130
Founded in 1993
Key Executives for ACADIA Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $245.6K
Chief Medical Officer and Executive Vice President of Development
Total Annual Compensation: $544.0K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $489.6K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $457.0K
Compensation as of Fiscal Year 2014.
ACADIA Pharmaceuticals Inc. Key Developments
ACADIA Pharmaceuticals Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:00 AM
Sep 4 15
ACADIA Pharmaceuticals Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:00 AM. Venue: Sofitel Hotel, New York, New York, United States.
ACADIA Pharmaceuticals Inc. Appoints Stephen R. Davis as President and Chief Executive Officer
Sep 3 15
Effective September 1, 2015, ACADIA Pharmaceuticals Inc.'s board of directors appointed Stephen R. Davis as President and Chief Executive Officer, effective from September 1, 2015. Mr. Davis continues to function as ACADIA's Chief Financial Officer. Mr. Davis, age 54, has served as ACADIA's Interim Chief Executive Officer since March 2015 and as its Executive Vice President, Chief Financial Officer and Chief Business Officer since July 2014. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals Inc. He recently served on the boards of directors of Synageva BioPharma Corp., Heron Therapeutics, and Furiex Pharmaceuticals Inc.
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID for the Treatment of Parkinson’s Disease Psychosis
Sep 3 15
ACADIA Pharmaceuticals Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. NUPLAZID is an SSIA (selective serotonin inverse agonist) preferentially targeting 5-HT2A receptors. Through this novel mechanism, NUPLAZID has demonstrated significant efficacy in Parkinson’s disease psychosis (PDP) and has the potential to avoid many of the debilitating side effects of existing antipsychotics, none of which are approved for use in PDP patients. The FDA granted NUPLAZID Breakthrough Therapy designation for PDP in 2014. According to the National Parkinson Foundation, about one million people in the United States and from four to six million people worldwide suffer from Parkinson’s disease. An estimated 40% of these patients have Parkinson’s disease psychosis, which is characterized by hallucinations and delusions. Currently, there is no FDA-approved therapy to treat Parkinson’s disease psychosis. ACADIA has requested a Priority Review of its NDA. If granted, Priority Review status would accelerate the review timeline from ten months to six months following the conclusion of the 60 calendar day filing review period that begins on the FDA’s receipt of the NDA. The FDA informs the applicant of a Standard or Priority Review designation following the conclusion of this 60 calendar day period.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|